Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Active RA according to the revised ACR (1987) criteria or EULAR/ACR (2010) criteria~* Moderate to severe RA with a DAS28-ESR score \>3.2 points~* Inadequate response and/or intolerance to MTX or other non-biologic DMARDs and/or where MTX or other non-biologic DMARDs are inappropriate~* Oral corticosteroids (less than or equal to \[\</=\] 10 mg per day prednisolone or equivalent) and nonsteroidal anti-inflammatory drugs (NSAIDs) permitted if on stable dose regimen for greater than or equal to \[\>/=\] 4 weeks prior to baseline~* Permitted non-biologic DMARDs allowed if at stable dose for \>/=4 weeks prior to baseline~* Receiving treatment on an outpatient basis, not including tocilizumab~* Agreement to use reliable means of contraception as defined by protocol, among females of childbearing potential and males with female partners of childbearing potential~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline~* Rheumatic autoimmune disease other than RA~* Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis~* Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16~* Prior history of or current inflammatory joint disease other than RA~* Exposure to tocilizumab or any other biologic DMARDs at any time prior to baseline~* Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening~* Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline~* History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies~* Evidence of serious concomitant disease or disorder~* Known active current or history of recurrent infection~* Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening~* Active tuberculosis requiring treatment within the previous 3 years~* Positive for hepatitis B or hepatitis C~* History of or current active primary or secondary immunodeficiency~* Pregnant or lactating women~* Neuropathies or other conditions that might interfere with pain evaluation~* Inadequate hematologic, renal, or liver function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab Alone or Combined with Methotrexate or Other DMARD (Type: EXPERIMENTAL): All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete